Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577278 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00577278 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 41 participants.
The verdict
NCT00577278, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor that do not exactly match the patient's blood, are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and sirolimus before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects and how well giving indium In 111 ibritumomab tiuxetan and yttrium y 90 ibritumomab tiuxetan together with rituximab, fludarabine, melphalan, and donor stem cell transplant works in treating patients with B-cell non-Hodgkin lymphoma.
Interventions
- BIOLOGICAL rituximab
- DRUG fludarabine phosphate
- DRUG tacrolimus
- DRUG melphalan
- DRUG sirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-10-03 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577278
The ClinicalTrials.gov registry entry for NCT00577278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00577278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577278 about?
NCT00577278 is a clinical study titled "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan". RATIONALE: Giving monoclonal antibody therapy, radioimmunotherapy, and chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor that do not exactly...
What is the current status of trial NCT00577278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-10-03. Estimated completion is 2023-12-14.
What interventions are being tested in trial NCT00577278?
The interventions under investigation include: rituximab (BIOLOGICAL), fludarabine phosphate (DRUG), tacrolimus (DRUG), melphalan (DRUG), sirolimus (DRUG).
Who is sponsoring clinical trial NCT00577278?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.